Navigation Links
Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
Date:5/1/2008

Company to Provide Financial Guidance for Fiscal 2008 through 2010

PITTSBURGH, May 1 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it will host a conference call and live webcast on Thursday, May 8, 2008, at 5 p.m. ET to provide a review of the first quarter ended March 31, 2008. The company also will provide updated financial guidance for fiscal 2008 through fiscal 2010 and an operational and integration update on Merck Generics, which the company acquired on Oct. 2, 2007. The company will release its financial results after the market closes May 8.

The dial-in number to access the May 8 call is 877-719-9810 or 719-325-4793 for international callers. A replay, available for approximately seven days, will be available at 888-203-1112 or 719-457-0820 for international callers with access pass code 4576196.

To access a live webcast of the May 8 call, please log on to Mylan's Web site (http://www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on http://www.mylan.com for approximately seven days.

Mylan Inc., with operations in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest-and highest quality-product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information about Mylan, visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Declares Quarterly Preferred Stock Dividend
2. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
3. Mylan Announces Final FDA Approval for Trandolapril Tablets
4. Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
5. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
6. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
7. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
8. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
9. Mylan Restores Availability of Generic Levothyroxine in Florida
10. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
11. Mylan Declares Quarterly Preferred Stock Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... The Association of Home Care Coding & ... Health and Hospice ICD-10 Transition Workgroup are working closely with the American Hospital ... to address concerns over the use of 'A' as the seventh character indicating ...
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
(Date:2/8/2016)... ... , ... The schedule is now online for the largest and ... is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues to give ... of chronic illness in children. , Very recent articles have cited 1 child in ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Calif. , Feb. 8, 2016  HemaFlo Therapeutics, Inc. ... (USPTO) has issued US Patent Number 9,119,880 covering the use ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ... --> Dale Peterson , PhD, HemaFlo,s founder, ... a powerful technology." --> Dale Peterson ...
(Date:2/8/2016)... Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka ... as president, Americas Operations, for Astellas US LLC, with responsibility ... America , effective April 1, 2016.  Robinson previously served ... the United States -- a role ... who is retiring in June 2016.  --> ...
(Date:2/8/2016)... 8, 2016 --> ... by Allied Market Research titled, "World Synthetic ... 2014-2020", estimates the world synthetic biology market to ... sequencing technology segment would continue to lead the ... segment, collectively, held around half of the market ...
Breaking Medicine Technology: